Haleon plc (NYSE:HLN), a leading company in the consumer health sector, known for brands like Sensodyne and Panadol, recently announced its earnings for the fourth quarter of 2025. On February 26, 2026, HLN reported an earnings per share (EPS) of $0.259, exceeding the analysts' expectations of $0.251. However, the company faced a slight hiccup in its revenue generation, posting approximately $7.52 billion, which was marginally below the forecasted $7.57 billion.
During its Q4 2025 earnings call, as reported by Seeking Alpha, Haleon provided insights into its financial performance and strategic direction. The company achieved an organic growth rate of 3% for the year, which did not meet its 4-6% medium-term growth target. This shortfall was attributed mainly to challenges encountered in the North American market, which accounts for 35% of Haleon's revenues. The region saw a 0.4% decline in organic growth, influenced by a cautious American consumer base amid inflation and labor market concerns, particularly impacting discretionary categories such as Smokers' Health and multivitamins. Despite these hurdles, Haleon reported double-digit profit growth and strong cash generation, underscoring its robust long-term prospects.
Further dissecting Haleon's financial health, the company's price-to-earnings (P/E) ratio stands at approximately 14.47, showcasing the market's valuation of its earnings. Its price-to-sales ratio is about 2.10, indicating its market value in relation to sales. The enterprise value to sales ratio is around 2.57, offering a comparison of the company's total value to its sales. Additionally, the enterprise value to operating cash flow ratio is approximately 37.62, highlighting its cash flow generation in relation to its valuation. The earnings yield is about 6.91%, providing insight into the return on investment. With a debt-to-equity ratio of 0.53, Haleon maintains a moderate leverage level. Lastly, a current ratio of approximately 0.87 indicates its short-term liquidity position.
